Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to Ring The Nasdaq Stock Market Opening Bell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III Data
April 1, 2016 11:52 AM EDTBaird reiterated an Outperform rating and $526.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's release of Dupilumab's phase III atopic dermatitis phase III data. The two Phase III studies, SOLO 1 and SOLO 2, enrolled 1,379 adult patients with moderate-to-severe AD. The FDA's... More
